Table 5.
Clinical success at TOC by baseline pathogen
| Pathogen | Micro-ITT population [n (%)]a |
ME population [n (%)] |
||
|---|---|---|---|---|
| Solithromycin 800/400 mg (N = 18) | Levofloxacin 750 mg (N = 14) | Solithromycin 800/400 mg (N = 15) | Levofloxacin 750 mg (N = 13) | |
| Gram-positive aerobes | ||||
| S. aureus | 1/1 (100.0) | 3/3 (100.0) | 1/1 (100.0) | 3/3 (100.0) |
| S. pneumoniae | 4/7 (57.1) | 2/3 (66.7) | 3/5 (60.0) | 2/3 (66.7) |
| Streptococcus acidominimus | −b | 0/1 (0.0) | − | 0/1 (0.0) |
| Streptococcus pyogenes | 1/1 (100.0) | 1/1 (100.0) | 1/1 (100.0) | 1/1 (100.0) |
| Streptococcus spp. | 1/1 (100.0) | − | 1/1 (100.0) | − |
| Gram-negative aerobes | ||||
| H. influenzae | 2/3 (66.7) | 3/4 (75.0) | 1/2 (50.0) | 3/4 (75.0) |
| H. parainfluenzae | 1/1 (100.0) | − | 1/1 (100.0) | − |
| Klebsiella oxytoca | 1/1 (100.0) | − | 1/1 (100.0) | − |
| K. pneumoniae | − | 1/2 (50.0) | − | 1/2 (50.0) |
| M. catarrhalis | 1/1 (100.0) | 0/1 (0.0) | 1/1 (100.0) | − |
| Pseudomonas aeruginosa | − | 1/1 (100.0) | − | 1/1 (100.0) |
| Atypical pathogens | ||||
| C. pneumoniae | 1/1 (100.0) | 0/1 (0.0) | 1/1 (100.0) | 0/1 (0.0) |
| M. pneumoniae | 1/1 (100.0) | − | 1/1 (100.0) | − |
a
n, number of patients with clinical success; N, number of patients with the specified baseline pathogen; %, 100 × (n/N).
b
−, pathogen not isolated.